DBV Technologies S.A.(DBV)

Description: DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

---

Keywords: Biopharmaceutical Immunotherapy Milk Allergy Inflammatory Bowel Disease I Diabetes Celiac Disease Immunotherapy Products Immunoglobulin E Atopy Food Allergies Eosinophilic Esophagitis Food Allergy Peanut Allergy Dbv Technologies Immune System Disorders Peanut Allergies Cow's Milk Protein Allergy Epicutaneous Immunotherapy Products Milk Allergy Viaskin Milk

---

Home Page: www.dbv-technologies.com

177-181 Avenue Pierre Brossolette
Montrouge, 92120
France
Phone: 33 1 55 42 78 78

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)